Dean Rudge
Senior Reporter
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Eylea Race Continues To Heat Up With Formycon Unveiling Early Positive Data
Weeks after Coherus BioSciences put pen to paper on a deal to bring in Formycon’s FYB203 proposed biosimilar to Eylea (aflibercept), the candidate has shown positive efficacy and safety data, according to preliminary Phase III trial results.
Lannett Eyes Another $11M In Savings With R&D Sea Change, Job Cuts
Lannett unveiled another round of cost-saving initiatives alongside its financial Q2 earnings, including plans for a radical change for its R&D development.
Is There A Biosimilar Future For A Smaller Target Like Synagis?
With something of a revolution in the RSV space on the horizon, Generics Bulletin looks at the potential for biosimilar competition in developed markets to AstraZeneca/SOBI’s existing benchmark option, the 25-year-old prophylactic Synagis (palivizumab).
What Does Teva’s Exit From PhRMA Suggest About Its Priorities?
Seemingly in one of the first decisions overseen by the company’s new CEO Richard Francis, Teva will not sit at the table of the US brand industry trade association, the Pharmaceutical Research and Manufacturers of America, better known as PhRMA.
Amarin Investor Heat Intensifies, Despite ‘Unprecedented’ Vascepa Fortitude
The brouhaha between Amarin and its largest shareholder has continued apace, with a smorgasbord of verbal volleys launched against the company, ahead of Amarin’s general meeting of shareholders later this month.
Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals
The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.